Select Language
Siglec-2
Siglec-2 Overview
| English Name | CD22 | Approved Drugs | 2 |
| Drugs in Clinical Trials | 75 | Target Synonym | B-Lymphocyte Cell Adhesion Molecule，SIGLEC2，BL-CAM，Siglec-2，Sialic Acid Binding Ig-like Lectin 2，B-cell receptor CD22，Sialic acid-binding Ig-like lectin 2，T-cell surface antigen Leu-14，CD22，CD22 Molecule，CD22 Antigen |
| Highest Development Stage | Approved | ||
| English Name | CD22 |
| Target Synonym | B-Lymphocyte Cell Adhesion Molecule，SIGLEC2，BL-CAM，Siglec-2，Sialic Acid Binding Ig-like Lectin 2，B-cell receptor CD22，Sialic acid-binding Ig-like lectin 2，T-cell surface antigen Leu-14，CD22，CD22 Molecule，CD22 Antigen |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 75 |
| Highest Development Stage | Approved |
Siglec-2 Product List
- Product Category
Protein (18)Beads (1)Cell Grade Beads (1)
- Product Status
Launched (20)
- Species
Human (15)Mouse (2)Rhesus macaque (1)Rat (1)Canine (1)
- Tag
His Tag (12)Fc Tag & Avi Tag (1)Llama IgG Fc Tag (1)Fc Tag (3)His Tag & Avi Tag (1)- (2)
- Conjugate
Unconjugated (8)Biotin-labeled (4)FITC Labeled (2)PE Labeled (1)- (2)AF555 Labeled (1)AF488 Labeled (1)APC Labeled (1)
Add to Cart
Total: 20
- 1
- 2
Siglec-2 Background
B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.
Siglec-2 Synonyms
CD22,SIGLEC2,BL-CAM,SIGLEC-2,Siglec2,SIGLEC2FLJ22814
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Suciraslimab | SM-03; SM-06 | Phase 3 Clinical | Lonn Ryonn Pharma Ltd, Sinomab Bioscience Ltd | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Pemphigoid, Bullous | Details |
| GC-022 | GC-022; GC-022F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti CD22 CAR-T cell therapy (Shanghai Yake Biotechnology) | Phase 2 Clinical | Beijing Gao Boren Hospital Co Ltd, Chengdu USino Technology Biology Co Ltd, Shanghai YaKe Biotechnology Co Ltd, The First Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CART22-cells | CART22-cells; JJO686 | Phase 2 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Leukemia, B-Cell; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD22-CAR T cell therapy (Kecellitics Biotech) | Phase 2 Clinical | Kecellitics Biotech Company Ltd | Leukemia; Lymphoma; Lymphoma, B-Cell | Details | |
| Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Leukemia; Lymphoma | Details | |
| Anti-CD22 CAR-T cell therapy (No. 307 Hospital) | Phase 2 Clinical | The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| UCART-20x22 | UCART-20x22 | Phase 2 Clinical | Cellectis Sa | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| TAC-001 | TAAC-001 | Phase 2 Clinical | Tallac Therapeutics Inc | Solid tumours | Details |
| CD19/22 CAR-T cells therapy (Minsk Scientific-Practical Center For Surgery) | Phase 2 Clinical | Minsk Scientific-Practical Center For Surgery, Transplantation And Hematology | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| AZD-4512 | AZD-4512; AZD4512 | Phase 2 Clinical | Astrazeneca Plc | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Autoimmune Diseases; Hematologic Neoplasms; Neuroblastoma | Details |
| KQ-2002 | KQ-2002 | Phase 2 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Leukemia, B-Cell; Lymphoma, B-Cell; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Fourth-gen CAR T Cells Targeting CD19/CD22 therapy(Essen Biotech) | Phase 2 Clinical | Essen Biotech | Central Nervous System Lymphoma; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD19/CD22 Bispecific CAR-T Cell Therapy(Beijing Tongren Hospital) | Phase 2 Clinical | Beijing Tongren Hospital, Cmu | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD19/CD22 CAR-T cell therapy (The First Affiliated Hospital Of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) | Phase 2 Clinical | Kk Women'S And Children'S Hospital | Leukemia, Lymphoid; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | 4SCAR19/22 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, B-Cell; Lymphoma, B-Cell | Details |
| Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) | CT-120 | Phase 2 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| CD19/CD22 dual-target CAR-T (Yake biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| SCRI-CAR22v2 | Phase 2 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma | Details | |
| CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) | Phase 2 Clinical | Federal Research Institute of Pediatric Hematology Oncology and Immunology | Burkitt Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Lasmecabtagene timgedleucel | UCART-22 | Phase 2 Clinical | Cellectis Sa | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| JCAR-018 | JCAR-018 | Phase 2 Clinical | National Cancer Institute, Opus Bio | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Hebei Senlang Biotechnology) | Senl_H19x22 | Phase 2 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia, B-Cell; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| TRPH-222 | CD22-4AP; TRPH-222; CAT-02-106 | Phase 1 Clinical | Catalent Inc | Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
| Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) | Phase 1 Clinical | Shanghai General Hospital, Shanghai Jiaotong University | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) | Phase 1 Clinical | Orca Biosystems Inc, Stanford University | Leukemia, Lymphoid; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD19/CD22 CAR-T cell therapy (Shenzhen BinDeBio) | Phase 1 Clinical | Dehe Biotech Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD22 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD19- and CD22 specific CAR (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma | Details | |
| RD-102 | RD-102 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse | Details |
| dual anti-CD19/anti-CD22 CAR T-cell therapy (Seattle Children's Hospital) | SCRI-CAR19X22v1 | Phase 1 Clinical | Seattle Children'S Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| YT-19/22 | Phase 1 Clinical | China Immunotech Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| TriCAR T-cells | Phase 1 Clinical | Children'S Hospital Los Angeles | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| anti-CD19/anti-CD22 CAR T-cell therapy (MD Anderson Cancer Center/National Cancer Institute) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital) | Phase 1 Clinical | Southern Medical University Zhujing Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD22/CD19 monoclonal antibody-toxin conjugate | Phase 1 Clinical | University of Texas Southwestern Medical Center | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| B-019 | B-019 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Leukemia, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Central Nervous System Lymphoma; Leukemia, Lymphoid | Details | |
| (186)Re-epratuzumab | Phase 1 Clinical | University Medical Center Nijmegen | Lymphoma, Non-Hodgkin | Details | |
| CD20/CD19/CD22 Multi-targeted Chimeric Antigen Receptor T-cell (CAR-T) Therapy (Unicar-Therapy Bio-Medicine Technology) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Lymphoma, B-Cell | Details | |
| DuoCAR20.19.22-D95 | DuoCAR20.19.22-D95 | Phase 1 Clinical | The University Of Kansas Medical Center | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CAR1922T2 T cells therapy(Tongji Hospital) | CAR1922T2 | Phase 1 Clinical | Tongji Hospital | Lymphoma, Non-Hodgkin | Details |
| CD19/CD22 CAR-T Cell Therapy(Guangzhou Women And Children'S Medical Center) | Phase 1 Clinical | Guangzhou Women And Children'S Medical Center | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy(St. Jude Children'S Research Hospital) | Phase 1 Clinical | St. Jude Children'S Research Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Autologous CD19/CD22 CAR T cells therapy(Instituto De Investigación Hospital Universitario La Paz) | Phase 1 Clinical | Instituto De Investigación Hospital Universitario La Paz | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| UB-VV400 | UB-VV400 | Phase 1 Clinical | Iaso Biotherapeutics Ltd, Umoja BioPharma Inc | Autoimmune Diseases; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| UB-VV410 | UB-VV410; IASO-302 | Phase 1 Clinical | Iaso Biotherapeutics Ltd, Umoja BioPharma Inc | Autoimmune Diseases; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma, Non-Hodgkin | Details |
| BZE-2204 | BZE2204; BZE-2204 | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic | Details |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells therapy(Stanford University) | Phase 1 Clinical | Stanford University, The Leukemia And Lymphoma Society | Burkitt Lymphoma; Leukemia; Leukemia, Hairy Cell; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Waldenstrom Macroglobulinemia | Details | |
| Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy(Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing GoBroad Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| SC-262 | SC-262; SC-263 | Phase 1 Clinical | Sana Biotechnology Inc | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| AUTO-1-NG | AUTO-1-NG; AUTO1/22 | Phase 1 Clinical | Autolus Therapeutics Plc, University College London | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Autologous CD22 targeting CAR-T cells therapy(British Columbia Cancer Agency) | CLIC-2201 | Phase 1 Clinical | British Columbia Cancer Agency | Leukemia, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma | Details |
| Firicabtagene autoleucel | CRG-022 | Phase 1 Clinical | Cargo Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Sarcoma; Solid tumours; Uterine Cervical Neoplasms | Details | |
| REGN5837 | REGN5837; REGN-5837 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Lymphoma, Non-Hodgkin | Details |
| bispecific CD19/CD22 CAR T-cell therapy （University of Colorado） | Phase 1 Clinical | University Of Colorado | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
| LCAR-AIO | LCAR-AIO; VHH CAR-T | Phase 1 Clinical | Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Neuromyelitis Optica; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| ThisCAR-T-22(Fundamenta Therapeutics) | ThisCAR-T-22 | Phase 1 Clinical | Fundamenta Therapeutics Ltd | Leukemia, B-Cell; Lymphoma, B-Cell | Details |
| CD19x22 CAR T Cell Therapy (University Of Colorado Denver) | Phase 1 Clinical | University Of Colorado, Denver, Usa | Central Nervous System Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) | HX-s001; YTS101; HX-s001/YTS101; HXYT-001 | Phase 1 Clinical | Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd | Leukemia, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| HY-004 (Juventas) | HY-004 (Juventas) | Phase 1 Clinical | Juventas Cell Therapy Ltd | Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-human CD19-CD22 T cell therapy | HR004 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Central Nervous System Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Rezetamig | JNJ-8780; JNJ75348780; JNJ-75348780 | Phase 1 Clinical | Teneobio Inc | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) | Phase 1 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Lymphoma, B-Cell; Multiple Myeloma | Details | |
| CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Hematologic Neoplasms | Details | |
| CTA-101 | CTA-101 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) | Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| HY-004 (Juventas Cell Therapy) | Clinical | Juventas Cell Therapy Ltd | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma | Details | |
| Anti-CD22 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti CD19/CD22 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Moxetumomab pasudotox | HA-22; GCR-8015; CAT-8015 | Approved | Astrazeneca Plc | Lumoxiti | United States | Leukemia, Hairy Cell | Innate Pharma | 2018-09-13 | Leukemia; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Lymphoma; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Inotuzumab Ozogamicin | WAY-207294; PF-5208773; CMC-544; PF-05208773 | Approved | Celltech Group plc, Wyeth Pharmaceutical Co Ltd | Besponsa | EU | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Pfizer Europe Ma Eeig | 2017-06-28 | Burkitt Lymphoma; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Leukemia; Leukemia, B-Cell; Leukemia, Myelogenous, Chronic; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland